23 January 2014 in Medical Physics
Purpose:: We report on the clinical process, quality assurance, and geometric and dosimetric results of the first clinical implementation of electromagnetic transponder‐guided MLC tracking which occurred on 28 November 2013 at the Northern Sydney Cancer Centre.Methods:: An electromagnetic transponder‐based positioning system (Calypso) was modified to send the target position output to in‐house‐developed MLC tracking code, which adjusts the leaf positions to optimally align the treatment beam with the real‐time target position. Clinical process and quality assurance procedures were developed and performed. The first clinical implementation of electromagnetic transponder‐guided MLC tracking was for a prostate cancer patient being treated with dual‐arc VMAT (RapidArc). For the first fraction of the first patient treatment of electromagnetic transponder‐guided MLC tracking we recorded the in‐room time and transponder positions, and performed dose reconstruction to estimate the delivered dose and also the dose received had MLC tracking not been used.Results:: The total in‐room time was 21 min with 2 min of beam delivery. No additional time was needed for MLC tracking and there were no beam holds. The average prostate position from the initial setup was 1.2 mm, mostly an anterior shift. Dose reconstruction analysis of the delivered dose with MLC tracking showed similar isodose and target dose volume histograms to the planned treatment and a 4.6% increase in the fractional rectal V60. Dose reconstruction without motion compensation showed a 30% increase in the fractional rectal V60 from that planned, even for the small motion.Conclusions:: The real‐time beam‐target correction method, electromagnetic transponder‐guided MLC tracking, has been translated to the clinic. This achievement represents a milestone in improving geometric and dosimetric accuracy, and by inference treatment outcomes, in cancer radiotherapy.
1 October 2016 in Radiotherapy and Oncology
1 January 2015 in Medical Physics
Purpose: Kilovoltage intrafraction monitoring (KIM) is a real‐time image guidance method that uses widely available radiotherapy technology, i.e., a gantry‐mounted x‐ray imager. The authors report on the geometric and dosimetric results of the first patient treatment using KIM which occurred on September 16, 2014.Methods: KIM uses current and prior 2D x‐ray images to estimate the 3D target position during cancer radiotherapy treatment delivery. KIM software was written to process kilovoltage (kV) images streamed from a standard C‐arm linear accelerator with a gantry‐mounted kV x‐ray imaging system. A 120° pretreatment kV imaging arc was acquired to build the patient‐specific 2D to 3D motion correlation. The kV imager was activated during the megavoltage (MV) treatment, a dual arc VMAT prostate treatment, to estimate the 3D prostate position in real‐time. All necessary ethics, legal, and regulatory requirements were met for this clinical study. The quality assurance processes were completed and peer reviewed.Results: During treatment, a prostate position offset of nearly 3 mm in the posterior direction was observed with KIM. This position offset did not trigger a gating event. After the treatment, the prostate motion was independently measured using kV/MV triangulation, resulting in a mean difference of less than 0.6 mm and standard deviation of less than 0.6 mm in each direction. The accuracy of the marker segmentation was visually assessed during and after treatment and found to be performing well. During treatment, there were no interruptions due to performance of the KIM software.Conclusions: For the first time, KIM has been used for real‐time image guidance during cancer radiotherapy. The measured accuracy and precision were both submillimeter for the first treatment fraction. This clinical translational research milestone paves the way for the broad implementation of real‐time image guidance to facilitate the detection and correction of geometric and dosimetric errors, and resultant improved clinical outcomes, in cancer radiotherapy.
1 April 2018 in Radiotherapy and Oncology
Until now, real-time image guided adaptive radiation therapy (IGART) has been the domain of dedicated cancer radiotherapy systems. The purpose of this study was to clinically implement and investigate real-time IGART using a standard linear accelerator. We developed and implemented two real-time technologies for standard linear accelerators: (1) Kilovoltage Intrafraction Monitoring (KIM) that finds the target and (2) multileaf collimator (MLC) tracking that aligns the radiation beam to the target. Eight prostate SABR patients were treated with this real-time IGART technology. The feasibility, geometric accuracy and the dosimetric fidelity were measured. Thirty-nine out of forty fractions with real-time IGART were successful (95% confidence interval 87-100%). The geometric accuracy of the KIM system was -0.1 ± 0.4, 0.2 ± 0.2 and -0.1 ± 0.6 mm in the LR, SI and AP directions, respectively. The dose reconstruction showed that real-time IGART more closely reproduced the planned dose than that without IGART. For the largest motion fraction, with real-time IGART 100% of the CTV received the prescribed dose; without real-time IGART only 95% of the CTV would have received the prescribed dose. The clinical implementation of real-time image-guided adaptive radiotherapy on a standard linear accelerator using KIM and MLC tracking is feasible. This achievement paves the way for real-time IGART to be a mainstream treatment option.
1 November 2018 in International Journal of Radiation Oncology, Biology, Physics
1 August 2015 in International Journal of Radiation Oncology, Biology, Physics